IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter M. Glazer and Pamela A. Havre

Serial No: Continuation of 08/083,088 Express Mail Label

No. EL 709 418 853 US

Filed:

February 14, 2001

Date of Deposit: February 14, 2001

For:

CHEMICALLY MODIFIED OLIGONUCLEOTIDE FOR SITE-DIRECTED

MUTAGENESIS

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

REQUEST FOR APPROVAL OF DRAWING CHANGES AND PRELIMINARY AMENDMENT

Sir:

I. Request for Approval of Drawing Changes

Pursuant to 37 C.F.R. § 1.121(a)(3), applicants respectfully request approval for changes to the drawings indicated in red on the attached photocopies of the informal drawings of Figures 1-9, and respectfully request entry of the following amendment to conform the specification to the requested changes to the drawings.

Applicants no longer have the original photographs for Figures 2, 5b, 6, and 8 in parent application U.S.S.N. 08,083,088 filed June 25, 1993. Therefore, the changes are made to cancel Figures 2, 5b, 6, and 8, and to relabel the drawings accordingly. Figures 3a and 3b are now Figures 2a and 2b. Figure 4 is now Figure 3. Figure 5a is now Figure 4. Figure 7, which is

Continuation of U.S.S.N. 08/083,088 Filed: February 14, 2001

REQUEST FOR APPROVAL OF DRAWING

CHANGES AND PRELIMINARY AMENDMENT

Express Mail Label No. EL 709 418 853 US Date of Deposit: February 14, 2001

described in the specification as Figures 7A and 7B, is now Figures 5A and 5B, to conform to the

description in the specification, as amended. Figure 9 is now Figure 6.

Accordingly, an amendment to the application is required to refer to the renumbered

figures. Pursuant to 37 C.F.R. § 1.84(u), applicants have deleted references to the canceled

figures in the specification to correspond to the new labeling.

II. **Preliminary Amendment**

Prior to examination, please amend the application as follows.

In the Specification

On page 1, after the title and before "Background of the Invention", please insert the

following paragraph:

-- This application is a continuation of U.S. Serial No. 08/083,088 filed June 25, 1993.--

On page 5, line 17, after "pso-AG10 (4" and before "hydroxymethyl", please insert a

hyphen ("-").

On page 5, line 18, after "trimethylpsoralen-5 AGGAAGGGGG3")", please insert

--(SEQ ID NO:1)--.

On page 5, please delete lines 24-33.

On page 5, line 34, please delete "3A and 3B", and insert --2A and 2B-- in place thereof.

On page 5, line 37, please delete "3A", and insert --2A-- in place thereof.

On page 6, line 13, please delete "3B", and insert --2B-- in place thereof.

2

1323687v1 YU 109 CON (OCR 470) 20003/17 Continuation of U.S.S.N. 08/083,088 Filed: February 14, 2001 REQUEST FOR APPROVAL OF DRAWING CHANGES AND PRELIMINARY AMENDMENT Express Mail Label No. EL 709 418 853 US Date of Deposit: February 14, 2001

On page 6, line 16, please delete "Figures 1 and 2", and insert --Figure 1-- in place thereof.

On page 6, line 23, please delete "Figure 4", and insert -- Figure 3-- in place thereof.

On page 6, line 26, please delete "8-trimethyl" and insert --8-trimethylpsoralen-- in place thereof.

On page 6, line 27, after "5 AGGAAGGGGG3)", please insert --(SEQ ID NO:1)--.

On page 7, line 9, please delete "Figures 5A and 5B show", and insert --Figure 4 shows--in place thereof.

On page 7, line 10, please delete "Figure 5A", and insert -- Figure 4-- in place thereof.

On page 7, please delete lines 24-37.

On page 8, please delete lines 1-29.

On page 8, line 30, please delete "Figures 7A and 7B", and insert --Figures 5A and 5B--in place thereof.

On page 8, line 34, please delete "7A", and insert --5A-- in place thereof.

On page 9, line 11, please delete "7B", and insert --5B-- in place thereof.

On page 9, please delete lines 18-37.

On page 10, line 1, please delete "Figure 9", and insert -- Figure 6-- in place thereof.

On page 15, lines 10-11, please delete "as shown in Fig. 2".

On page 15, line 36, please delete "and is reproduced in Figure 2".

Continuation of U.S.S.N. 08/083,088 Filed. February 14, 2001

REQUEST FOR APPROVAL OF DRAWING

CHANGES AND PRELIMINARY AMENDMENT

Express Mail Label No. EL 709 418 853 US Date of Deposit: February 14, 2001

On page 15, line 36, please insert -- The electrophoretic gel showed binding of the triplex

forming oligonucleotide "AG10" to the supF gene target. To assay for triplex formation,

³²P-labeled oligonucleotides, either AG10 (⁵ AGGAAGGGGG³) (SEQ ID NO:2) or the reverse

sequence oligomer (GA10), were incubated with a 240 bp double-stranded fragment containing

the entire <u>supF</u> gene. The products of the binding reactions were visualized by polyacrylamide

gel electrophoresis and autoradiography.--

On page 16, line 1, please delete "As shown in Figure 2, binding", and insert --Binding--

in place thereof.

On page 16, line 2, please delete "(lane 2)".

On page 16, line 6, please delete "(lane 1)".

On page 16, line 7, please delete "(lane 3)".

On page 16, line 9, after "GGGGGAAGGA 3)", please insert --(SEQ ID NO:3)--, and

delete "(lane 4)".

On page 16, line 11, please delete "(lane 5)".

On page 16, line 12, please delete "(lane 6)" and "(lane 7)".

On page 16, line 13, please delete "(lane 8)".

On page 17, lines 5-6, please delete "As shown in Figure 2,".

On page 18, line 9, after "(5 CCCCCTTC 3)", please insert --(SEQ ID NO:4)--.

On page 19, line 7, please insert -- (SEQ ID NO:1)-- under "pso-5 AGGAAGGGGG3".

Continuation of U.S.S.N. 08/083,088 Filed: February 14, 2001 REQUEST FOR APPROVAL OF DRAWING CHANGES AND PRELIMINARY AMENDMENT Express Mail Label No. EL 709 418 853 US Date of Deposit: February 14, 2001

On page 19, line 8, please insert --(SEQ ID NO:5)-- under "pso-5 GGGGGAAGGA3".

On page 19, lines 9 and 10, please insert --(SEQ ID NO:1 and SEQ ID NO:4)-- under "pso-5 AGGAAGGGGG3" and under "3 CTTCCCCC5", respectively.

On page 19, line 12, please insert --(SEQ ID NO:1)-- under "pso-5 AGGAAGGGGG".

On page 20, line 8, please delete "Fig. 3a", and insert -- Figure 2a-- in place thereof.

On page 20, line 35, please delete "Figure 3b", and insert --Figure 2b-- in place thereof.

On page 21, line 3, please delete "Fig. 3b", and insert -- Figure 2b-- in place thereof.

On page 24, line 13, please delete "Fig. 4", and insert -- Figure 3-- in place thereof.

On page 24, line 15, after "(5 AGGAAGGGGG3)", please insert --(SEQ ID NO:2)--.

On page 24, line 16, after "(5 GGGGGAAGGA3)", please insert --(SEQ ID NO:3)--.

On page 25, line 24, after "3", please insert -- (SEQ ID NO:6)--.

On page 25, line 25, after "TCC CCC 3", please insert -- (SEQ ID NO:7).

On page 27, line 21, please delete "Fig. 4", and insert -- Figure 3-- in place thereof.

On page 27, line 28, after "5 AGGAAGGGGG3", please insert -- (SEQ ID NO:2).

On page 28, lines 25-26, please delete "Fig. 5a and illustrated in Fig. 5b", and insert --Figure 4-- in place thereof.

On page 28, line 26, before "Digestion", please insert --A gel demonstrated site-specific formation of triplex DNA in the <u>supF</u> gene by psoralen-AG10 using a restriction enzyme protection assay. Analysis by agarose gel electrophoresis of *Hinf* I digestions of the 250 bp <u>supF</u>

Continuation of U.S.S.N. 08/083,088 Filed: February 14, 2001

REQUEST FOR APPROVAL OF DRAWING CHANGES AND PRELIMINARY AMENDMENT

Express Mail Label No. EL 709 418 853 US Date of Deposit: February 14, 2001

gene PCR fragment under various conditions was done. The <u>supF</u> fragment was incubated with or without psoralen-AG10 at a 100-fold molar excess, treated by 1.8 J/cm² of UVA irradiation, and then subjected to *Hinf* I digestion.--.

On page 28, line 27, please delete "yields", and insert --yielded--.

On page 28, line 28, plese delete "(lane 1)".

On page 28, line 29, please delete "(lane 6)".

On page 28, line 31, please delete "(lane 3) results", and insert --resulted--.

On page 28, lines 33-34, please delete "demonstrated by the appearance of".

On page 28, line 34, after "fragment", please insert --appeared--.

On page 29, line 1, please delete "(lane 4)".

On page 29, line 3, please delete "(lane 2)".

On page 29, line 18, please delete "Fig. 6 illustrates", and insert --A gel experiment showed site-specific formation of triplex DNA in the SV40 vector as a function of the ratio of oligonucleotide to SV40 DNA. Binding of psoralen-AG10 as a triple strand to bp 167-176 of the supF gene within the SV40 vector was assayed by examining protection from *Hinf* I digestion at bp 164-168, as diagrammed in Figure 4. The SV40 vector containing the supF target gene (50nM) was incubated with psoralen-AG10 at ratios of oligomer to vector of from 1:1 to 1000:1, irradiated with 1.8 J/cm² of UVA, digested with *Hinf* I, and run on a 4.5% Nusieve gel. Because the sequences flanking the supF gene in the SV40 DNA differ from those in the PCR fragment,

Continuation of U.S.S.N. 08/083,088 Filed: February 14, 2001 REQUEST FOR APPROVAL OF DRAWING CHANGES AND PRELIMINARY AMENDMENT

Express Mail Label No. EL 709 418 853 US Date of Deposit: February 14, 2001

and since there are multiple Hinf I sites in SV40, the pattern of bands is more complex.--

On page 29, line 19, please delete "that".

On page 29, line 23, please delete "(arrow)".

On page 29, line 33, please delete "Fig. 4", and insert -- Figure 3-- in place thereof.

On page 31, line 12, please delete "Fig. 7A", and insert -- Figure 5A-- in place thereof.

On page 31, line 16, please delete "Fig. 7", and insert --Figures 5A and 5B-- in place

thereof.

On page 31, line 34, please delete "Fig. 7B", and insert -- Figure 5B-- in place thereof.

On page 33, line 11, after "sequences.", please insert --An analysis was done of <u>supF</u> gene mutations in the SV40 vector by a colony hybridization assay. Bacterial colonies containing SV40 plasmid vector DNA carrying <u>supF</u> gene mutations were grown and lysed *in situ* on nylon filters to allow nucleic acid hybridization. Oligonucleotide probes that either exactly matched the wild type sequence of the <u>supF</u> gene at base pairs 158-176 or matched the sequence of the 167 T:A to A:T transversion mutation at those base pairs were radioactively labeled and allowed to hybridize with duplicate filters under conditions designed to enable discrimination between mutant and wild type sequences. Binding was visualized by autoradiography.--.

Continuation of U.S.S.N. 08/083,088 Filed: February 14, 2001 REQUEST FOR APPROVAL OF DRAWING CHANGES AND PRELIMINARY AMENDMENT Express Mail Label No. EL 709 418 853 US

Date of Deposit: February 14, 2001

On page 33, lines 11-13, please delete "The results of one such analysis are shown in Fig. 8. Of the 19 colonies assayed in this particular experiment," and insert --Results showed in

On page 33, line 16, please delete "in the upper right hand corner".

this particular experiment that of the 19 colonies assayed,-- in place thereof.

On page 36, line 8, please delete "Figure 9", and insert -- Figure 6-- in place thereof.

Respectfully submitted,

Robert A. Hodges Reg. No. 41,074

Date: February 14, 2001

ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8796 (404) 873-8797 (fax)




Figure 1




Figure 2

Sa	Figure 🕉 🐔
	Figure

	5,	GTGGT	180	CACCA	1+ 3,		
13 V	cgr	TAGGAAGGGGGTC	160 * 170	ATCCTTCCCCCAC	+++++++++++++++++++++++++++++++++++++++		
K	T G CGT	CIICCAAGCI	160	GAAGGTTCGA	++++++++		
		STAGCTGAAG	150	CATCGACTIC	****		
		TAGACGGCAC	140	ATCIECCEIC	*******		
	H	SCTCTGAGATI	130	CAGACTCTAA	* * * * * * * * * * * * * * * * * * * *	++++	
	-	GGTTTCCCTC	120	CCAAAGGGAG		*****	99-183)
		AAGGGCTCGC	110			++++++++	pre-tRNA (58-98) Suppressor tRNA (99-183)
		ACACCACCCC	100		5555555	+	3) Suppres:
		TOGTAATGG	00		7	+	RNA (58-98
		(A T T T)	,	, K. K. F. C.	2000	+	pre-t
	Č	J TARABLE AND		40 30 SOLUTION CONTRACTOR CONTRAC	ALTICALGATOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOC	2, ++ ++ +	Promoter

Figure 🕉





Figure × 3



supF PCR fragment: 250 bp

complete Hinf I digestion: 150 bp, 65 bp, and 35 bp Hinf I site at 164-168 blocked or mutated: 150 bp and 100 bp

Figure 5/4 4




Figure 5b




Figure 6

GTAAAAGCATTACCTGTGGTGGGGTTCCCGAGCGGCCGAAAGGGAGCAGCTCTAAATCTGCCGTCATCGACTTCGAAGGTTCGAA<u>TCCTTCCCCG</u>ACCACCA TAAACTATACGEGGGG CATTITCGTAATGGACACCCCCAAGGGCTCGCCGGTTTCCCTCGTCTGAGATTTAGACGGCAGTAGCTGAAGCTTCCAAGCTTAGGAAGGGGGTGGTGGT 160 140 Figure 54

ATTTGATATGATGCGCCCC

5' ++ ++ Promoter

Figure 58

(A156-167) (A157-167) (A160-167) (A163-167)

 $(\Delta 167 - 169)$ (4167-169)

			2,	_)
				GGT	180	CCA	
				GGT	М.	CCA	
			ပ	25		ğ	
			AG C AA C	BGGG	120 130 140 150 160 * 170	22	
Æ	Æ	Æ	AA	BGGA	+	1221	
			S	CII	•-	GAA.	
	Æ	⋖	Æ	SAAG	1 60	STIC	
				TTC	• •	AAG(
	Ă	Ø	ď	AAGC		rrce	
				CTG	150	GAC	
				STAG		CATC	
				GCAC		CGT	
				SACG	140	TGC	
				TTAC		AATC	
	E-4	⊢	ΣŢ	AGAT	0	ICTA	
				CTG!	13(GAC	
				rcgr		AGCA	
				S	0	9550	
				GTTI	12	CAAA	
			E	Š		2000	
				CTCC	110	GAGC	
				9999	7	CCC	
			(מי מי)	GGTJ	
			C	ף ל ה	100	TGG	
				2	;	GTG	
				4 U E	1	ACCI	
				444	06	ATT	
				T T	2	AAGC	
				Ę	1	TAA	
				,	י י	G	
				3/ G TC AT AT ATTENDED AND AND ASSOCIATED AS	9	Y Y STITIGATATGEGECECE GIAAAAGCATTACCIGIGGGGIICCCGAGGGGCGGCCAAAGGGAGCAGCICIAAAICIGCCGICATCGACIICGAAGGIICGAA <u>ICCIICCCCC</u> ACCACCA STITIGAIAIGCGCCC GIAAAAGCAITGGAGGIICGAAICIGGGGGGGGGGGAGGAGGAGGAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAA	
			,	AT	797617	rgcg	
				É	T ACT	TGA	
	•	- E	י פיני		לואו	GATA	
		`	- '	3' G TC	IAMACIA	TII	
			,	m E	: -1	Ø	S

Colony hybridization assay



Wild type probe

Mutant probe bp 167 T->A

Figure 8




Figure 9
Figure 6